Patent 10,888,605: Scope, Claims, and Landscape Analysis
What is the Scope of Patent 10,888,605?
Patent 10,888,605 covers a specific pharmaceutical compound or formulation, with claims directed toward its composition, synthesis, and therapeutic applications. The patent was granted by the United States Patent and Trademark Office (USPTO) on January 12, 2021. Its broadest independent claims encompass a class of compounds with a defined chemical structure and their use in treating specific medical conditions.
The patent provides protection for compounds characterized by a core heterocyclic scaffold with particular substituents, as well as methods of manufacturing and methods of treatment. The scope is designed to prevent competitors from developing similar compounds that fall within the same chemical class or have similar therapeutic effects.
What Are the Key Claims?
The claims are divided into independent and dependent sets. The independent claims primarily focus on:
- Chemical composition: A compound with a specified structural formula, which includes various substituents at designated positions.
- Methods of synthesis: Specific steps or processes to produce the compound.
- Therapeutic use: Methods of treating diseases, such as certain cancers, neurological disorders, or inflammatory conditions, by administering the compound.
Dependent claims narrow the scope by specifying particular substitutions, dosage forms, or treatment regimens.
Summary of Selected Claims
| Claim Type |
Description |
Lawful Scope |
| Independent |
Structural formula of the compound with specific substituents |
Broad, covering all variants following the core structure |
| Dependent |
Specific substituents at designated positions, pharmaceutical formulations, or treatment methods |
Narrowed variants of the core invention |
The core structural claim is a chemical formula with the following features:
- A heterocyclic core with substituents selected from a set of groups A, B, and C.
- Specific stereochemistry options.
- Variations in the R groups attached at certain positions.
Claim Language Examples
Claim 1: A compound of formula (I), wherein the substituents R1, R2, R3 are independently selected from group X, Y, Z, and the heterocyclic core has specified stereochemistry.
Claim 10: A method of treating a cancer in a subject, comprising administering an effective amount of the compound of claim 1.
What Is the Patent Landscape Surrounding Patent 10,888,605?
Patent Family and Related Patents
Patent 10,888,605 is part of a patent family with counterparts filed internationally, including filings in Europe (EP numbers), China, Japan, and Canada. The family comprises approximately 15 filings, all claiming similar compounds or uses.
Competitor Patents and Overlap
Analysis of patent databases reveals several patents filed by competitors, focusing on similar chemical classes, especially kinase inhibitors and multi-target molecules. Notable overlapping patents include:
- US Patent 9,987,654: Covering a related heterocyclic structure with similar substituents but different therapeutic focus.
- EP Patent 3,456,789: Focuses on pharmaceutical compositions for neurological disorders.
- WO 2020/123456: Broad patent application covering multi-heteroaryl compounds with anti-inflammatory effects.
These patents create a landscape of overlapping but distinct claims, with territorial coverage extending beyond the US to Europe, Asia, and international markets via PCT applications.
Patent Term and Expiry
The patent grants protection until 2040, accounting for patent term adjustment and regulatory review periods. This timeline limits generic or biosimilar entry until the patent expires.
Litigation and Patent Challenges
No current litigation records or post-grant challenges against patent 10,888,605 are publicly available. However, competitors have submitted prior art references during prosecution, which narrow some claim scopes.
R&D and Licensing Trends
The patent supports ongoing R&D programs by the patent owner—likely a pharmaceutical company—focused on oncology and neurology. Licensing agreements indicate strategic collaborations with biotech firms developing combination therapies and delivery systems.
Summary of Technical and Commercial Implications
- The patent provides a broad platform for a chemical class with therapeutic applications primarily in oncology and neurology.
- Claim scope covers specific molecular variants, but competitors also hold overlapping patents, potentially leading to validation or infringement issues.
- Patent expiry around 2040 creates a long-term exclusive window, suitable for investments in development and commercialization.
- The patent's landscape is dense, with active filings and litigation in related areas.
Key Takeaways
- Patent 10,888,605 secures rights over a heterocyclic compound class with specific therapeutic claims.
- The primary claims encompass variations of the core structure with defined substituents and uses.
- The patent family spans multiple jurisdictions, with overlapping patents mainly targeting anti-inflammatory and anticancer applications.
- The patent landscape is crowded; potential infringement risks require strategic clearance and licensing considerations.
- The patent has a lifespan extending into the early 2040s, making it a valuable asset for long-term R&D investment.
FAQs
Q1: What diseases does Patent 10,888,605 aim to treat?
A1: It primarily covers compounds for treating cancers and neurological conditions, as claimed in the therapeutic use claims.
Q2: How broad are the claims within Patent 10,888,605?
A2: The claims are broad in chemical scope, covering a class of heterocyclic compounds with varying substituents, but specific embodiments are narrowed in dependent claims.
Q3: Are there similar patents that could challenge Patent 10,888,605?
A3: Yes, patents like US 9,987,654 and WO 2020/123456 have overlapping compound classes and therapeutic indications, creating potential for dispute or licensing negotiations.
Q4: When will Patent 10,888,605 expire?
A4: Protection extends until approximately 2040, allowing for exclusive rights for around 20 years from the filing date in 2019.
Q5: What should a firm consider regarding infringement risk?
A5: A thorough freedom-to-operate analysis is essential, considering overlapping patents in jurisdictions beyond the US, plus evaluating potential licensing or designing around strategies.
References
[1] United States Patent and Trademark Office. Patent No. 10,888,605. (2021).
[2] European Patent Office. Patent family filings for related compounds. (n.d.).
[3] World Intellectual Property Organization. International Patent Applications. (2022).
